Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cellular immunity in Hodgkin's disease.

S H Advani, H D'Silva, B P Gothoskar

    Cancer
    |February 1, 1979
    PubMed
    Summary

    Cell-mediated immunity (CMI) is impaired early in Hodgkin's disease (HD) and persists post-treatment. This immune defect, affecting lymphocytes, contributes to anergy in HD patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.

    Indian journal of cancer·2017
    Same author

    The Pattern of Malignant Lymphoma in India: A Study of 1371 Cases.

    Leukemia & lymphoma·2016
    Same author

    Clinical evaluation of sahacharadi and nirgundi tailas in saisaveeyavata (poliomyelitis).

    Ancient science of life·2012
    Same author

    Conversation with Dr. K. A. Dinshaw. [Interviewed by Meena Tiwari].

    Journal of cancer research and therapeutics·2011
    Same author

    Cancer survival in Barshi, India, 1993-2000.

    IARC scientific publications·2011
    Same author

    Visfatin--a review.

    European review for medical and pharmacological sciences·2011

    Area of Science:

    • Immunology
    • Oncology
    • Hematology

    Background:

    • Cell-mediated immunity (CMI) defects are observed early in Hodgkin's disease (HD).
    • These immune impairments can persist for up to two years after successful HD treatment.
    • Understanding these defects is crucial for managing HD patients.

    Purpose of the Study:

    • To investigate the nature and persistence of CMI defects in Hodgkin's disease patients.
    • To correlate in vivo and in vitro measures of immune function.
    • To identify potential therapeutic targets for immune restoration in HD.

    Main Methods:

    • In vivo skin testing with dinitrochlorobenzene (DNCB).
    • In vitro leukocyte migration inhibition (LMI) assays using phytohemagglutinin (PHA).

    Related Experiment Videos

  • Assessment of serum inhibitory effects and lymphocyte responsiveness to levamisole.

    • Main Results:

    • A strong correlation was found between in vivo DNCB response and in vitro LMI against PHA.
    • Sera from HD patients exhibited inhibitory effects on leukocyte migration in vitro.
    • Levamisole augmented the response of peripheral leukocytes from HD patients, indicating intrinsic lymphocyte defects.

    Conclusions:

    • Hodgkin's disease is associated with persistent CMI defects affecting multiple immune system sites.
    • Intrinsic lymphocyte dysfunction contributes to immune anergy in HD patients.
    • These findings highlight the complex immunological dysregulation in Hodgkin's disease.